Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Agendia Moving to Decentralized Testing Model in Europe, Exploring Options for Asia Expansion

Agendia Moving to Decentralized Testing Model in Europe, Exploring Options for Asia Expansion

Apr 05, 2018
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) – Agendia is in the process of moving from a centralized testing model of offering tests via a service laboratory to a decentralized one of selling kits or working with local partners to reach customers.

The change will be felt most immediately in Europe, where the Dutch molecular diagnostics company recently secured a CE-IVD mark for its next-generation sequencing-based MammaPrint BluePrint Breast Cancer Recurrence and Molecular Subtyping Kit.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Molecular Diagnostics

  1. FDA Revises Emergency Use Authorization for Abbott Point-of-Care SARS-CoV-2 Test

  2. Illumina to Acquire Grail for $8B in Cash and Stock

  3. FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

    Premium

  4. CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

  5. FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.